GlassScriptPhysician profile
Nicole Baldwin
NPI 1033253778
$24,463.88
in general payments reported to CMS, 2019-2025
26 companies · $21K in 2025
The $21K reported for 2025 was more than what 99% of Adolescent Medicine (Pediatrics) providers received nationally (typical 2025 total: $99.31).
See the full distribution for Adolescent Medicine (Pediatrics)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371 · 2020: $262 · 2021: $344 · 2022: $307 · 2023: $318 · 2024: $1,676 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Travel and Lodging: $2,549 · Food and Beverage: $1,421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,210.00 |
| Travel and Lodging | $2,548.99 |
| Food and Beverage | $1,420.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $22,211.33 | 2024-2025 | |
| Corium, LLC | $392.31 | 2021-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $307.90 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $223.30 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Ironshore Pharmaceuticals INC. | $221.02 | 2019-2023 | Jornay Pm |
| Cranial Technologies, INC | $175.62 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $133.83 | 2022-2025 | Qelbree, Qelbree |
| Pfizer INC. | $126.97 | 2019-2025 | |
| Neos Therapeutics, LP | $92.63 | 2019-2025 | Cotempla Xr-Odt |
| Tris Pharma INC | $91.17 | 2019-2024 | Dyanavel Xr |
| Kaleo, INC. | $89.49 | 2019-2023 | Auvi-Q |
| Glaxosmithkline, LLC. | $62.43 | 2019-2022 | |
| Seqirus USA INC | $55.62 | 2023-2024 | Flucelvax, Flucelvax Quadrivalent |
| Novo Nordisk INC | $48.11 | 2025 | Wegovy, Ozempic |
| Sanofi Pasteur INC. | $31.05 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $30.46 | 2021 | |
| Ironwood Pharmaceuticals, INC | $23.99 | 2024 | |
| Soleno Therapeutics, INC. | $21.31 | 2025 | Vykat Xr |
| Rhodes Pharmaceuticals L.P. | $18.98 | 2019 | |
| Covis Pharma Gmbh | $17.89 | 2020 | |
| Qiagen, LLC | $15.76 | 2024 | |
| Collegium Pharmaceutical, INC. | $15.69 | 2025 | Jornay Pm |
| Avion Pharmaceuticals | $15.61 | 2024 | Methylphenidate Hydrochloride |
| Ultragenyx Pharmaceutical INC. | $14.45 | 2022 | |
| Dermira, INC. | $14.10 | 2020 | |
| Vertical Pharmaceuticals, LLC | $12.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Baldwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.